Streetbeat News

Products Services

DARE

Daré Bioscience has reported additional findings from its exploratory Phase 2B RESPOND study of Sildenafil Cream in women with sexual arousal disorder. The results showed statistical significance and clinically meaningful improvement in the co-primary endpoint assessing arousal sensation.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:11 pm

CBAY

CymaBay Therapeutics has announced the publication of two-year safety and efficacy results of Seladelpar in patients with Primary Biliary Cholangitis. The results show positive outcomes, indicating the drug's potential for long-term use.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:04 pm

OCUL

Ocular Therapeutix has received FDA agreement under Special Protocol Assessment for its first pivotal clinical trial of OTX-TKI in Wet AMD.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:03 pm

VTVT

vTv Therapeutics Inc. (NASDAQ:VTVT) has sold all of its common stock in Reneo Pharmaceuticals for approximately $4.4 million. The proceeds will support vTv's preparations for the launch of the cadisegliatin Phase 3 program in type 1 diabetes. vTv remains eligible to receive up to $94.5 million in milestones, as well as royalties on potential sales of products under the Reneo license agreement.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:02 pm

TGTX

TG Therapeutics reported over 900 prescriptions for Briumvi, indicated for relapsing forms of Multiple Sclerosis, in Q3 FY23. This marks approximately 2,200 prescriptions since its launch in January, from over 500 healthcare providers at over 250 centers.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 11:37 am

TRI

Thomson Reuters (TRI) has announced the launch of its Generative AI strategy, with the new technology being incorporated into its flagship product, Westlaw Precision. The updated product will be available in the US from November 15.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 11:34 am

KZIA

Kazia Therapeutics has announced a preliminary update from the ongoing investigator-initiated Phase 2 clinical trial of Paxalisib as monotherapy treatment in patients with relapsed/refractory primary central nervous system lymphoma.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 11:30 am

SLCA

U.S. Silica has announced price increases on its industrial and specialty products. The price increase is due to rising costs in production, labor, and logistics.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 11:30 am

CLGN

Collplant Biotechnologies has announced a US patent for its photocurable dermal filler product candidate, which is being developed for the aesthetics market.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 11:29 am

AAPL

Apple Inc.'s Weather app has a bug that prevents it from displaying snow, instead showing a generic file icon. The issue has been reported by several iPhone users on social media, who have been making fun of the bug. It is unclear whether the problem is a server-side issue, an app issue, or related to the latest iOS 17 update. Apple has not yet acknowledged the bug.

Portfolio Pulse from Rounak Jain

November 01, 2023 | 11:25 am